Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy

Adriana Albini1,2*, Antonino Bruno1†, Douglas M. Noonan1,3‡ and Lorenzo Mortara3‡

1 Scientific and Technology Pole, IRCCS MultiMedica, Milano, Italy, 2 Department of Medicine and Surgery, University Milano-Bicocca, Monza, Italy, 3 Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy

The critical role of angiogenesis in promoting tumor growth and metastasis is strongly established. However, tumors show considerable variation in angiogenic characteristics and in their sensitivity to antiangiogenic therapy. Tumor angiogenesis involves not only cancer cells but also various tumor-associated leukocytes (TALs) and stromal cells. TALs produce chemokines, cytokines, proteases, structural proteins, and microvesicles. Vascular endothelial growth factor (VEGF) and inflammatory chemokines are not only major proangiogenic factors but are also immune modulators, which increase angiogenesis and lead to immune suppression. In our review, we discuss the regulation of angiogenesis by innate immune cells in the tumor microenvironment, specific features, and roles of major players: macrophages, neutrophils, myeloid-derived suppressor and dendritic cells, mast cells, γδT cells, innate lymphoid cells, and natural killer cells.

Anti-VEGF or anti-inflammatory drugs could balance an immunosuppressive microenvironment to an immune permissive one. Anti-VEGF as well as anti-inflammatory drugs could therefore represent partners for combinations with immune checkpoint inhibitors, enhancing the effects of immune therapy.

Keywords: angiogenesis, chemoprevention, tumor microenvironment, immune cells, immunotherapy

INTRODUCTION

The “gradient” of phenotype, genetic, and epigenetic features of transformed cells inside the tumor gives rise to the most known and studied tumor heterogeneity, the “intrinsic” one. However, increasing attention is devoted to “extrinsic” heterogeneity, i.e., all those cellular and molecular “players” that include the non-cancerous hosting environment. Cancers develop in complex tissue environments, both in the primary and in the target organs of metastasis. A “hostile” setting is elicited, such as low oxygen, acidity, and altered metabolic conditions. Cancer cells adapt more rapidly than healthy ones to the adverse conditions that paradoxically sustain growth, invasion, and metastasis. In such an “infernal” environment, interactions between tumor cells and the associated stroma represent a dangerous relationship that reciprocally influences disease initiation, progression and, in the end, determines patient prognosis (1).

The confirmed theory that the presence of inflammatory cells plays a crucial role within the tumor microenvironment (TME) is a very old one (2). “Evading immune destruction” and “tumor-promoting inflammation” are recognized host-dependent tumor hallmarks as defined by Hanahan and Weinberg (3). Among the tumor-friendly phenomena generated through the activity of the
inflammatory cells in the microenvironment, there is the orchestration of angiogenesis, a biological phenomenon necessary to bring oxygen, nutrition to the tumors, and last but not least, to transport the cancer cell to metastatic sites (4–7). Innate immune cells, as a consequence of their plasticity, have been reported to acquire an altered phenotype that can be proangiogenic. For many immune cells, both from innate and adaptive immunity, the release of proangiogenic cytokines is accompanied by a switch to a tolerogenic/immunosuppressive behavior (4, 7–9). In this review, we choose to describe the role in angiogenesis of selected major classes of inflammatory cells: macrophages, neutrophils, myeloid-derived suppressor cells (MDSCs), dendritic cells (DCs), mast cells (MCs), gammadelta (γδ) T type 17 cells (γδT17), innate lymphoid cells (ILCs), and natural killer (NK) cells (Figure 1). We also sustain the rationale behind using antiangiogenic drugs before the onset of immunotherapy and we propose as an innovative, low-cost strategy the use of “repurposed” anti-inflammatory/chemopreventive drugs to assist immunotherapies.

**MACROPHAGES**

Macrophages constitute professional phagocytes of the innate immune cell compartment with different specialized functions, depending on the type of danger signals and endogenous molecules to which they are exposed (10). They act as sentinels in all tissues of the body against invading pathogens, are able to

---

**TABLE**

| Phenotype | M1-like | M2-like (TAM) |
|-----------|---------|---------------|
| IL-12, IFNγ, IL-1, CXCL9, CXCL10, CXCL11 | VEGF, MMP1, 7, 9, 12; PIGF, FGF2, PDGF, HGF, Angiopoietin1, COX-2, TNFα, IL10, Arginase1 |
| N1-like | IL-10, VEGF, MMP-9, CXCL8, HGF, PAF |
| N2-like (TAN) | CXCL8, TNFα, VEGF, TGFβ |
| RegDC | VEGF, MMP9, TGFβ, EC-transdifferentiation |
| Mast cells | TGFβ, VEGF, FGF2, CXCL8, MMP9, Chymase, Tryptase |
| CD56brightCD16−VEGFhighPIGFhighCXCL8+ NK | VEGF, PIGF, CXCL8 |
| ILC1 | IL12, IFNγ |
| ILC2 | IL-5, IL-13 |
| ILC3 | CXCL12, CCL19, CCL21, CXCR5, CCR7, IL-17 |
| γδT | IFNγ |
| γδT17 | IL-17, VEGF, Angiopoietin1, CXCL8, CCL2, CSF2, TNFα, MMP9, uPA, CXCL16, STAT3 |
trigger an inflammatory response, and collaborate with other immune cells to activate adaptive T lymphocyte responses through antigen processing and presentation. These activities are related to a classical activation state, which is type 1 T helper (TH1) cell associated and INFγ and/or LPS-dependent, and is referred to as M1. This condition is favorable to immune response. Macrophages can be alternatively activated by IL-4 and/or IL-13 signals from TH2 cells, eosinophils, and/or basophils in the surrounding microenvironment. This polarization is involved in parasite control and wound healing and is termed M2 (11). M2 macrophages are associated with chemical and physical tissue damage in which they mediate tissue homeostasis and repair \textit{via} remodeling and angiogenesis, in a spectrum of differentiation states. \textit{In vivo}, the plasticity and diversity of macrophages are responsible of a spectrum of different activation states strictly depending on an array of concordant but also discordant stimuli, such as hypoxia, chemokines, colony-stimulating factor 1 (CSF1), TGFβ, adenosine, and prostaglandin E2 (PGE2), that do not fit with the M1/M2 classification (12). For these reasons, M1-like is the preferred term used in this review and indicate a polarization state of macrophages that are able to orchestrate cytotoxic antipathogen and antitumor responses, whereas M2-like are cells that have the common functional feature of favoring tumor cell fitness, new blood vessel formation, as well as suppressive activities toward adaptive immune cells (13, 14). Tumor-associated macrophages (TAMs), which share many features with M2-like macrophages (Figure 2), represent the major cell population of tumor-infiltrating leukocytes (15). TAMs also show consistent differences between diverse types of cancers (16, 17). Elevated TAM infiltration has been correlated with poor clinical outcome in many types of cancers, such as ovarian, breast, prostate, cervical, and thyroid cancers, Hodgkin’s lymphoma, cutaneous melanoma, lung, and hepatocellular carcinomas (14, 18–22). Conversely, other reports on colorectal, prostatic, and lung cancers have detected a positive role of infiltrating macrophages favoring increased patient survival (23–25). During cancer development, macrophages are recruited in the tumor stroma by several inflammatory mediators, such as chemokines: CCL2 (also known as MCP-1), CCL5, CXCL12 (also known as SDF-1), cytokines: vascular endothelial growth factor (VEGF), CSF1, and activated complement elements. Blood monocytes, blood monocyte MDSCs, cells, or tissue-resident macrophages (26–28) are subverted in their phenotype and functions to differentiate into TAMs (14). However, TAMs are not fixed in an irreversible
phenotype, they maintain their plasticity and eventually could be targeted by specific therapeutic approaches to re-educate them to M1-like antitumor functions (29). Accumulating evidence have shown that TAMs can act as key cellular mediators, interconnecting chronic inflammation with cancer development and progression (3, 30).

Several lines of research have pointed out the role of TAMs in the regulation of tumor cell invasion, angiogenesis, lymphangiogenesis, and metastasis (11, 19). In primary tumors (Figure 2), they can promote angiogenesis (the "angiogenic switch") triggering the activation and the recruitment of endothelial cells (ECs), essentially by producing multiple proangiogenic factors, including VEGFA, epidermal growth factor (EGF), basic fibroblast growth factor 2 (FGF2), chemokines CXCL8 (also known as IL-8), CXCL12, TNFα, semaphorin 4D, adrenomedullin, and thymidine phosphorylase (31–34). These factors produced by TAMs are responsible for the proliferation of ECs and the induction of sprouting, tube formation, and maturation of new vessels. Macrophages have been shown to play a critical role in tumor lymphangiogenesis by producing VEGFC and VEGFD (35–37). TAM activities can also have an impact on degradation and remodeling of the extracellular matrix (ECM), through the production of different classes of enzymes and proteases, such as matrix metalloproteinases (MMPs in particular MMP2 and MMP9), plasmin, urokinase plasminogen activator (uPA), and cathepsins, thereby influencing tumor invasion and the metastatic process (38–40).

Tumor-associated macrophages are also associated with resistance to different chemotherapeutic agents, involving the activation of distinct molecular pathways. In breast cancers, TAMs are able to inhibit apoptosis of cancer cells upon paclitaxel treatment via induction of IL-10/signal transducer and activator of transcription (STAT)3/Bcl-2 signaling (41). In patients with non-small cell lung cancer, TAMs or M2-like TAMs dampen the responsiveness to targeted therapy with EGF receptor–tyrosine kinase inhibitors (42, 43).

A highly proangiogenic M2-like TAM subset is represented by angiopoietin responsive Tie2+ perivascular macrophages (35–37), which are able to induce chemotherapeutic drug resistance, favoring decreasing cancer cell responsiveness to radiotherapy (44). Specific inhibition of the angiopoietin/Tie2 axis can act in synergy with antiangiogenic treatments (45). Apart from their proangiogenic features, TAMs also play a crucial role in promoting an immunosuppressive milieu helping different tumors to escape immunosurveillance (46). Their contribution to tumor progression act also through crosstalk with other leukocytes and inflammatory and stromal cells (7, 47) within the TME. In the establishment of the immunosuppressive milieu, TAMs can directly recruit T regulatory (Treg) cells, by producing CCL20 (48) and CCL22 chemokines (49) and can activate them by secreting IL-10 and TGFβ (26). TAMs also represent an important factor for the establishment of the premetastatic niche (50, 51).

Different TAM-targeted therapeutic strategies have been developed with the aim to inhibit macrophage recruitment, to induce cell death, and to re-educate killer functions. These innovative therapeutic approaches could behave as a complement strategy in combination with antiangiogenic, cytoreductive, and/or immune checkpoint inhibitor treatments, and preclinical and clinical trial results are promising (14, 30, 52). CCL2-specific inhibition by antibodies has proven efficacious in mouse models of prostate, breast, lung, and melanoma, and this approach was synergistic with chemotherapy (53, 54). Different antibodies targeting CCL2 have entered phase I and II clinical trials (55). A CCR5 antagonist has been approved for the treatment of patients with liver metastases from advanced colorectal cancers and experimental data indicate that CCL5/CCR5 axis targeting could be suitable for clinical responses (56). Diverse compounds and antibody inhibitors that have been developed to inhibit the CSF1–CSF1R axis, could target TAM, and were evaluated in mouse models and in patients with different types of cancer (57). In diffuse-type tenosynovial giant-cell tumor showing overexpression of CSF1R, after treatment with CSF1R-blocking agents, patients experienced relevant clinical regressions (57, 58). In preclinical glioblastoma multiforme model, CSF1R blockade did not affect the TAM numbers but the M2-like TAM polarization markers were lowered, thus was associated with improvement of survival (59). Bisphosphonates, that are used to treat osteoporosis and to prevent bone metastases-related complications, can also be used to target macrophages inside the tumor (60). Moreover, bisphosphonates in combination with chemotherapy or hormonal therapy have been shown clinical synergistic effects, in different types of cancer patients, in particular for patients with breast cancer (61). In a murine model of pancreatic ductal adenocarcinoma (PDAC), the anti-CD40- and gemcitabine-treated mice induced re-education of M2-like TAM toward an M1-like macrophage and elicited effective antitumor responses (62). This lead to a phase I clinical trial in PDAC patients, the combination was well tolerated and provided some antitumor efficacy (63). A recently identified potent compound that targets TAMs is trabectedin, a synthetic form of a molecule isolated from the marine tunicate Ecteinascidia turbinata, which has found application in the treatment of soft tissue sarcomas and ovarian cancer patients. Trabectedin induces selective TRAIL-dependent apoptosis of monocytes, macrophages, and the monocytic component of MDSCs in blood, spleen, and tumors with the reduction of TAM numbers and angiogenesis (64, 65).

**NEUTROPHILS**

Neutrophils are the most abundant innate immune cells in the peripheral blood, they act as a first line of defense against invading pathogens and are crucial effectors in the acute phase of inflammation. Neutrophils are recruited in the damaged area by chemokines, in particular CXCL8, and the cognate receptors CXCR1 and CXCR2 (66). These leukocytes exert important functions such as phagocytosis, production and release of antimicrobial ROS, peptides, enzymes, and neutrophil extracellular traps (NET). Neutrophils can release a substantial quantity of different reactive soluble factors, including cytokines and chemokines (67), and are able to recruit and activate other immune cells, playing an important role in the regulation of chronic inflammation, tumor angiogenesis, and progression. Inflammatory CD66b+ neutrophils can be found in high numbers in either blood or TME of different cancers and correlated with poor clinical outcome (68–74).
Neutrophils produce either proangiogenic or antiangiogenic factors (75–79), and in some cases, such as in the early phases of lung cancers, they can exert important T cell stimulatory, antitumor functions (80). Although they are characterized by a terminally differentiated phenotype and a short half-life, these cells are endowed with a certain kind of plasticity and in murine tumor models they are able to differentiate in two distinct subsets: neutrophils type 1 (N1) with antimicrobial functions, and tumor-associated neutrophils (TANs or N2) endowed with protumor and proangiogenic features (Figure 2) in response to TGFβ (81, 82). In response to IFNγ, TAN/N2 neutrophils can be converted to N1 type in both mouse lung cancers and human melanomas (83, 84).

Accumulating evidence has indicated TANs as key players involved in tumor angiogenesis and metastatic process in both mice and humans (Figure 2). The complex role of TANs in tumor angiogenesis and metastasis resides mainly in the capacity of these cells to secrete an array of diverse immunosuppressive or proangiogenic molecules such as IL-1β, VEGF, FGF2, TGFα, hepatocyte growth factor (HGF), and angiopoietin 1 (ANG1) different chemokines such as CXCL1, CXCL8, CXCL9, CXCL10, CCL3, and CCL4 (6) and enzymes involved in ECM remodeling (MMP9). Production and expansion of neutrophils is dependent on CSF3 (G-CSF) and its receptor CSF3R. A crucial signaling pathway for cancer inflammation is STAT3 (85), which is downstream of activated CSF3R. In response to CSF3, neutrophils upregulate the expression of BV8 (also known as prokineticin-2) that induce myeloid cell mobilization and myeloid-dependent tumor angiogenesis (86). This production of BV8 depends on the activation of STAT3 (87). The tumor angiogenesis stimulation in mice by TANs and other myeloid cells is regulated by STAT3 activation, and expansion of MDSCs. These molecules contribute to the STAT3 activation of immature MDSCs, rendering them potent proangiogenic and immunosuppressive cells (106).

Immature myeloid cells (MDSC AND DC)

Immature myeloid cells are innate immunity cells that infiltrate the TME, having a critical role in the proangiogenic activities and in tumor immune evasion (Figure 1). The immature myeloid cells include MDSCs and DCs, also indicated as regulatory (reg) DCs (101, 102). The immature phenotype is due to constitutive activation of STAT3 that perturbs the differentiation process of these cells. MDSCs comprise in mice and humans two distinct immature myeloid cell types: the polymorphonuclear MDSC (PMN-MDSC) characterized by neutrophil features, and the monocytic MDSC (M-MDSC) having markers of monocytes. Recently, several articles have described exhaustively both MDSC and DC phenotypic characteristics and they will not be discussed here (103–105). Several tumor-derived factors, among which CSF3, IL-1β, and IL-6, have been implicated in recruitment, activation, and expansion of MDSCs. These molecules contribute to the STAT3 activation of immature MDSCs, rendering them potent proangiogenic and immunosuppressive cells (106).

Monocytic MDSCs have been intensively studied and recognized as immunosuppressive cells as well as proangiogenic effectors in cancer (107). Murine data suggested that MDSCs are also able to differentiate into ECs (108, 109). Recent data have suggested that MDSCs in human peripheral lymphoid organs are mainly represented by PMN-MDSCs, with immunoregulatory role and are involved in the tumor-specific T cell tolerance. In the TME, there is accumulation of the M-MDSC counterpart, which is more suppressive and can rapidly differentiate to TAMs. These events might imply that targeting only one myeloid cell subset (macrophages vs. granulocytes or vice versa) may not be sufficient for obtaining a long-lasting immunotherapeutic effect. An investigation performed in two transplantable and two transgenic tumor murine models has shown that the tumor-induced hypoxia triggers the upregulation of CD45 tyrosine phosphatase activity in TME residing MDSCs, resulting in downregulation of STAT3 and differentiation of MDSCs into TAMs (106). There is no hypoxia in the spleens, thus CD45 downregulation of STAT3 does not occur in this organ. Use of STAT3 inhibitors in tumor-bearing mice resulted in depletion of MDSCs in the spleen but not in tumors.
Myeloid-derived suppressor cells and TAMs are regulated by metabolic constraints within the TME, and this represents a crucial factor of the signaling network regulating the expression of specific transcriptional programs with distinct protumor functions (110). Several amino acids in the TME are converted to immunomodulatory molecules such as nitric oxide, polyamines, and kinurenines. Amino acids consumption by myeloid cells decrease the availability of essential nutrients for T cells (111). The energetic metabolism of tumor-infiltrating MDCs showed peculiar features in both mouse and human samples, such as a preferential augmented fatty acid uptake and their oxidation rather than glycolysis (112, 113). Targeting fatty acid oxidation inhibited tumor growth and combination with low dose chemotherapy blocked the MDSC immunosuppression (113). Myeloid cells in the TME produce increased fatty acid synthase in response to CSF1, which causes PPARβ/δ-dependent expression of genes, like VEGF, IL-10, and arginase 1 (Arg1), involved in the proangiogenic and immunosuppressive responses (114). A promising therapeutic approach is based on the reprogramming and the re-education of the metabolism of MDSCs in the TME, with appropriate drugs in combination with immune checkpoint inhibitors (115).

Myeloid-derived suppressor cells are also characterized by the ability to express high amounts of NADPH oxidase, which is responsible for the production of ROS in the form of superoxide anion, hydrogen peroxide, and peroxynitrite. MDSCs present also an increased expression of Arg1 and of inducible forms of nitric oxide synthase 2 genes, and they release diverse inhibitory cytokines, contributing to the immunosuppressive effects in the TME (116).

Myeloid DCs, also known as conventional (c)DCs, consists of multiple cell subsets with potent antigen-presenting cell capacity, therefore playing a fundamental role in the activation of T-cell adaptive responses against pathogens and tumor cells. However, tumor-associated cDCs or regulatory DC (regDCs) in the TME display altered functions with impaired cross-presentation capacity, express low levels of co-stimulatory molecules, and have high-proangiogenic abilities. These changes depend on diverse conditions that are established during tumor progression, for example, hypoxia, production of PGE2, IL-10, adenosine, and increased levels of lactate (117–119).

One of the major mechanisms contributing to DC dysfunction in tumor-bearing animals and in patients with different cancers is the abnormal accumulation of lipids (120). Growing evidence shows that cDCs can drive either immunosurveillance or accelerated tumor progression depending on the environment. In both mouse and human ovarian cancers, CCR6+ cDCs are recruited massively in the TME through the tumor-derived β-defensins and are induced to become proangiogenic cells, favoring tumor vascularization, and growth in response of tumor VEGF (121).

Depleting DC numbers in the tumor-bearing host at early stages of the disease correlates with faster tumor development in a murine model of ovarian cancer. DC inhibition at advanced stages induces on the contrary significant delays in the malignant progression (122).

During tumor progression, the hypoxia-induced regDCs remain in an immature state and acquire tolerogenic immunosuppressive properties and proangiogenic activities, for instance, by secretion of galec tin-1 (123, 124). Galectin 1 is able to bind VEGFR2 and neuropilin-1, mirroring the effect of VEGF on ECs, thereby promoting angiogenesis (123–125). Moreover, regDCs are involved in the expansion and activation of Treg cells through TGFβ release, reinforcing the induction of the immunosuppressive functions of the TME (126–128). Induction of adenosine receptor A2b is triggered by the hypoxia-induced factor (HIF)-regulated elements during tumor hypoxia and is involved in skewing DCs to TH2 triggering phenotype, sustaining M2-like macrophage induction, and reinforcing tumor angiogenesis (129). Although regDCs and MDSCs have cell-type specific functional properties, their capability of regulating tumor angiogenesis in the TME appears similar to the one of M2-like TAMs and N2 neutrophils, leading to production of several soluble factors such as VEGF, FGF2, BV8, and MMP9 (130).

**MAST CELLS**

MAst cells (MCs) are bone marrow-derived multifunctional immune cells first identified in human tumors by Paul Ehrlich in the 1870s (69, 131). MCs and their mediators exert a host protective immune response against noxious agents, viral and microbial pathogens (132–135), but are also associated with a detrimental role in allergic diseases (69). Increased number of MCs have been observed in tumor and peritumor tissues of cancer patients (136); their role in cancer insurgence and progression is tumor dependent (69, 131). Contrasting roles of MCs in supporting or inhibiting tumor progression have been reported (131). In solid neoplasms including thyroid, gastric, pancreatic, bladder cancers, prostate adenocarcinomas, and hematological malignancies, MCs have been associated with protumorigenic activity (69, 131, 137). In breast cancer (131) and in murine model of prostatic neuroendocrine tumors (137), MCs have antitumor activities. These data clearly suggest that the role of MCs in cancer is tumor-type dependent and is tuned by the local microenvironment (Figures 1 and 2).

Antitumor activities by MCs are related to their ability to induce target cell cytotoxicity by releasing TNFα or by induction of ROS. Protumorigenic activities of MCs include contribution to the induction of an acidic and immunosuppressive TME, through adenosine production in the extracellular milieu. Prometastatic functions of MCs are mediated by the release of TGFβ, which induce tumor cells to undergo epithelial to mesenchymal transition. MC releases proangiogenic factors including FGF2, VEGFA, TNFs, CXCL8 (69, 131), diverse proteases, such as MPPs (MMP9 mostly), as well as chymase and tryptase that modify pro-MPPs to their active forms (5, 138). MC deficient tumor-bearing mice show a reduced angiogenesis and metastatic capacity (138, 139). In renal cell carcinoma, infiltrating MCs have been found to support angiogenesis by modulating PI3K/AKT/GSK3β/AM signaling (140). Following activation of c-KitR/SCF, MCs can release tryptase that, acting on PAR2 in tumor cells, induce endothelial and tumor cell proliferation in a paracrine manner, leading to tumor cell invasion and metastasis (141). Tryptase released by MCs sustain angiogenesis in pancreatic cancers by activating the angiopoietin-1 pathway. Tryptase producing MCs correlate with angiogenesis in locally advanced colorectal cancer patients (142).
Immunohistochemical analysis showed that tryptase-positive MCs in multiple myeloma were associated with higher levels of MMP9, ANG2, and angiogenin (143) and could contribute to vasculogenic mimicry (144). Tryptase appears the key mediator for protumor activity of MCs, since it is involved in cell growth, tumor-induced angiogenesis, and invasion (145, 146), thus it appears to be a promising target for MC-related angiogenesis. Tryptase inhibitors originally designed as anti-allergic drugs could exert promising antitumor and antiangiogenic activity and could be proposed as repurposed drugs also in combination with immune therapy.

γδT17 CELLS

Gammadelta T cells are lymphoid cells characterized by unique features resembling innate cells in their capacity to recognize conserved non-peptide antigens expressed by stressed cells. They also resemble adaptive cells because of their ability to undergo clonal expansion and to develop antigen-specific memory (147). These cells are involved in the early phase of immune responses and produce pro-inflammatory factors such as IFNγ and TNFα and IL-17, activating other effector immune cells against virus, bacteria, and tumor cells but also stimulating inflammation and exacerbation of autoimmune diseases. They comprise different functional subsets.

Although there are some conflicting data on the role of γδT cells inside the TME, it is believed that the subset γδT17 cells, specialized in the IL-17 release, can actively participate in the angiogenic process (147, 148) (Figures 1 and 2). It has been shown that γδT17 cells release IL-17, CXCL8, CFS2 (also known as GM-CSF), and TNFα, and are able to support survival of MDSGs (149). Tumor cells over-expressing IL-17 showed significant tumor growth and new vessel formation (150). Since IL-17 has no direct effect on the proliferation of ECs, the proangiogenic effect is likely to be exerted through the enhancement of VEGF and/or CXCL8 by tumor cells (151). On the contrary, mice lacking IL-17 showed limited tumor growth and the vascular density in tumor tissues was decreased (152). There is evidence that IL-17 responsiveness can be an independent prognostic factor for overall survival in colorectal patients (153), high expression of IL-17 was shown to be associated with high microvessel density and was associated with VEGF production from tumor cells. More recently, it has been shown that IL-17 activates STAT3 in non-small cell lung carcinomas (NSCLC) cells and that treatment of HUVECs with IL-17 in vitro promoted the formation of vessel-like tubes in a dose-dependent manner (154). The GIV protein (Gα-interacting vesicle-associated protein, also known as Girdin) modulates the crucial signaling pathways in processes including macrophage chemotaxis, wound healing, and cancer metastasis and can be a target for STAT3 activation in NSCLC cell lines. IL-17-dependent STAT3/GIV signaling pathway is responsible for VEGF release from cancer cells and promotion of tumor angiogenesis, and GIV expression positively correlates with IL-17+ cell presence and increased microvessel densities and predicts poor survival of NSCLC patients (154).

IL-17 in the TME in the CMS-G4 fibrosarcoma tumor model was largely derived from tumor-infiltrating γδT cells, and anti-cytokine mAb treatment revealed that the γδT cells require the presence of IL-6, IL-23, and TGFβ signaling (152). In gallbladder cancer (GBC) patients, γδT17 cells are increased in peripheral blood and in the population of tumor-infiltrating lymphocytes (155). GBC patients with high γδT17, TH17, and Treg cells showed poor overall survival (155). A GBC (OCUG-1) cell line that is responsive to IL-17, treated with cell-free supernatant from γδT17 cells, upregulates VEGF production, and this effect is IL-17 dependent (155). The proangiogenic action of γδT17 cells on GBC was confirmed by protein angiogenesis array performed on cell-free supernatants derived from these cells. The assay showed IL-17-dependent upregulation of several important angiogenesis factors in OCUG-1 cells, such as VEGF, angiogenin, uPA, MMP9, CCL2, CXCL16, CSF2, and coagulation factor III, but also stimulation of production of antiangiogenic factors, including thrombospondin-1, TIMP1, serpine-1, and platelet factor 4. A recent report has shown that IL-17-secreting γδT cells are dependent on CCR6 for homing to inflamed skin (156). Drugs targeting CCR6 or factors involved in γδT17 cell proangiogenic polarization should be studied for potential use in addition with immunotherapy.

INNATE LYMPHOID CELLS

Innate lymphoid cells represent a recently identified heterogeneous family of mononuclear hematopoietic cells, found mostly in solid tissues (157–160). Based on their lymphoid morphology, surface antigens, transcription factor expression, and cytokine productions (TH1, TH2, and TH17-like), ILCs have been classified into three major groups, termed as ILC1, ILC2, and ILC3 (161). ILC1s are characterized by IFNγ release and are Tbet dependent; ILC2 produce type 2-cytokines, such as IL-5 and IL-13, and require GATA3 expression; ILC3s produce IL-17 and/or IL-22 and are dependent on RORγt (162). ILCs are endowed with potent pleiotropic effects in early responses against infections and are involved in several pathologies including cancer. Aberrant activation, proliferation, and functions of ILCs support severe inflammation and damages in diverse organs, including the gut, lung, liver, and skin (163–168). Whether ILCs can be defined as friends or foes in cancer insurgence and progression is still a matter of debate (157, 158, 160). ILCs are characterized by high-cell plasticity and can be easily interconverted into their different subsets upon TME stimuli [especially ILC1–ILC3 interconversion (169)].

IFNγ+ ILC1s have been associated with both antitumor and protumor effects (Figure 1), the latter induced by triggering of MDSCs and inducing indoleamine 2,3-dioxygenase activity (157). A protective role exerted by a novel type of ILC1-like cells has been shown in a murine model of mammary carcinogenesis (170). NK cells, that will be discussed, later have also been included in the ILC1 subclass.

ILC2s can release type 2 cytokines, such as IL-5 and IL-13, and CSF2 in response to IL-25 and IL-33. IL-13/IL-13R interaction in breast cancer and cholangiocarcinoma cells in association with recruitment and induction of TGFβ-producing MDSCs and Treg has been reported to induce tumor cell growth and migration (171), and tumor immune escape (172).
of IL-13 by ILC2s promotes M2-like TAM polarization and amplification (172).

Among the ILC subgroups, ILC3s are the more investigated for their contribution to carcinogenesis. They comprise several subsets: lymphoid tissue inducer (LI-Ti) cells, first discovered for their function in the formation of lymphoid tissue during organogenesis, NCR (NKp46, NKp44)+ ILC3 and NCR− ILC3. Overall, the pro-tumor activities of ILC3s are mainly linked to the induction of chronic inflammation by secretion of IL-17 and IL-22, in particular in the gut, through their response to IL-23 (173).

ILC3s preserve epithelial integrity and maintain tissue homeostasis by secretion of IL-22. Production of IL-17 by ILC3s can have a role in promoting tumorigenesis, tumor growth, and angiogenesis (174–176). Growing evidence from mouse tumor models marks ILC3s as cells involved in the recruitment of MDSCs, Treg cells, and in the promotion of M2-like macrophages in the TME. At the moment, the real contribution in human cancers remains to be fully elucidated (177, 178). ILC3s have also been shown to play a role in carcinogenesis in models of bacteria-induced colorectal cancer, through the release of IL-22 (179). The involvement of LTi-like ILC3s has been shown in the induction of tumor migration via lymphatics in patients with triple-negative breast cancers (180). In the 4T1.2 syngeneic mouse breast model, ILC3s are recruited in the primary tumor through CCL21, and then they trigger tumor stromal cells to release CXCL13, which leads to the induction of lymphotoxin receptor activator of nuclear factor κB ligand, that in turn promotes lymphangiogenesis and stimulate tumor cell motility (180). A correlation exists between invasive aggressive behavior in breast cancer patients and gene expressed by ILC3s such as CXCL13, CCL19, CCL21, and CXCR5 and CCR7 (181). ILC3s have been shown to promote the formation of tertiary lymphoid structures (TLS), involved in tumor progression and lymph nodal metastasis (182). The protumor or antitumor roles of TLS are still debated (183, 184). NKp46+ NKp44+ LTi-like ILC3s are present in the TME near intra-tumor TLS and may interact directly with tumor cells by sensing and recognizing transformed cells through the NKp44 receptor. Tumor-infiltrating NKp46+ NKp44+ LTi-like ILC3s are endowed with ability to release several types of pro-inflammatory cytokines and chemokines, and their increased numbers correlated with intra-tumor TLS and predict favorable clinical outcome (185). Accumulation of neuropilin (NRP)1+ LTi-like ILC3s has been found in inflamed tissues of patients with chronic obstructive pulmonary disease and in smokers, in association with VEGF production (186). Immunohistochemistry analysis of inflamed tissues revealed that the majority of RORγt+ NRP1+ cells were co-localized with blood vessels and in the alveolar parenchyma, suggesting their contribution to angiogenesis and induction of lung TLS. Apart from IL-22 and IL17, the pro-inflammatory LTi-like NRP1+ ILC3 subset was also found to release CSF2, TNFa, B-cell-activating factor, and CXCL8, possibly contributing to angiogenesis.

Due to the recent discovery of the non-NK ILCs and the incomplete knowledge of the role in tumor and angiogenesis, targeting strategies have not been yet developed.

**NK CELLS**

Natural killer cells are bone marrow-derived large granular effector lymphocytes of the innate immune system that can potentially control tumor growth by their cytotoxic activity (187), which are now classified as a subset of ILC1 (161). Based on surface density expression of CD56, an isoform of the human neural cell adhesion molecule, and of CD16, the low-affinity Fcγ receptor, two main subpopulations of peripheral blood NK cells have been identified in humans: the CD56dimCD16+ and the CD56brightCD16−low NK cell subset, representing about 90–95% of peripheral blood NK cells and about 5–10% of peripheral blood NK cells, respectively. CD56dimCD16+ NKs can release high quantity of perforin and granzymes and are cytotoxic when encountering cells with high-activating ligands and low inhibitory (mostly class I MHC) ligands or when mediating antibody-dependent cell cytotoxicity (187). Although weak long-term cytokine producers, these cells have the ability to quickly (2–4 h) secrete high amounts of cytokines (188, 189). CD56brightCD16−low NKs, are poorly cytotoxic, but can release several cytokines, including IFNy, TNFa, and GM-CSF. However, there is an increasing awareness of the complexity of NK cell subsets and the role of the TME (190–193). Mature NK cells express the PD-1 receptor, and engagement with the programmed death-ligand 1 (PD-L1) ligand results in impaired antitumor NK cell activity (194, 195). Disruption of this PD-1/PD-L1 interaction by blocking antibodies partially restores their antitumor activity (194, 195). Another recently identified NK checkpoint is the IL-1R8 (also known as SIGIRR, or TIR8), which is expressed on human and murine NK cells (196). Mice lacking IL-1R8 are protected against chemically-induced tumors and metastatic dissemination (196). Mice lacking the cytokine-induced SH2-containing protein CIS also had protection toward chemically induced tumors and metastatic disease (197).

A third NK cell subset has been identified in the decidua during pregnancy, termed decidual or uterine NK cells (dNK). dNK cells acquire the CD56brightCD16−KIR+ phenotype (198), are poorly cytotoxic, and secrete proangiogenic cytokines, including VEGF, placental growth factor (PIGF), CXCL8, and IL-10 (198–200) and are critical for decidual vascularization and spiral artery formation (199, 201). Early on in pregnancy, dNK increase up to 70% of the local lymphocytes and 30–40% of all decidual cells (202). While it has been exhaustively demonstrated that NK cells have important proangiogenic roles in the uterine vasculature, their contribution to tumor angiogenesis still represent a poorly explored topic (Figure 1). The TME has been extensively reported to be crucial in shaping NK cell functions (203). We were the first to report a proangiogenic NK cell polarization in peripheral blood (TANKs) and tumor-infiltrating NK cells (TINks) (204) in NSCLC patients. We showed that the CD56brightCD16− NK cells, the predominant subset infiltrating NSCLC tissues and a minor subset in adjacent lung and peripheral blood, are found with VEGF, PIGF, and IL-8 production (Figure 2). Functional assays indicated that supernatants derived from NSCLC CD56brightCD16− NK cells induce EC chemotaxis and formation of capillary-like structures in vitro, and that these effects were even stronger in TANKs isolated from subset of squamous carcinoma patients than in adenocarcinoma.
TGFβ is associated with dNK polarization (205, 206) and is present in the TME. A combination of TGFβ, hypoxia, and a demethylating agent induces a dNK-like phenotype in healthy donor NK cells (207). A recent report indicated that TGFβ converted NK cells into other ILC1 subpopulations that were unable to control local tumor growth and metastasis (208). We observed that TGFβ1 upregulates VEGF and PGF in healthy donor NK cells (204).

Tumor-infiltrating NK cells operate within a hypoxic TME. Hypoxia has been extensively reported to modulate immune cell response as well as driving angiogenesis (209). Murine NK cells genetically depleted of HIF1α continued to have impaired cell cytotoxicity, yet tumors grew more slowly in these mice (210). Tumors in these mice had numerous immature vessels with hemorrhages that resulted in severe hypoxia, which favored metastasis. Genetic inactivation of STAT5, which is necessary for NK cell-mediated cancer immunosurveillance, increases VEGFA in NK cells and stimulates angiogenesis in mouse lymphoma models and on healthy donor-derived NK cells (211). The aminobiphosphonate zoledronic acid, largely employed as an immunomodulatory agent and able to decrease VEGF levels, has been surprisingly found to synergize with IL-2 in inducing proangiogenic features in TINKs, acting on VEGF/VEGFR1 axis (212). Thus, therapeutic intervention could act as a double edge sword in NK cell response to tumors.

**PHARMACOLOGICAL AND IMMUNOTHERAPEUTIC COMBINATION TARGETING THE TME**

Extensive studies on TME led to a shift from a tumor-centered view of cancer onset to the role of a more complex tumor ecosystem in which cellular and molecular components are as influential as cancer cells themselves for cancer development and metastatic behavior. This knowledge led to the rapid development of therapeutic approaches aimed at restoring altered/aberrant host immune cell response, by accelerating/pushing efficient tumor eradication, stimulating immune cells of the host (213). The use of immune checkpoint blockers (ICBs) induces reactivation of key immune cell players and has been demonstrated to have great clinical benefits in several tumors (214). Available ICBs target cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1) receptor, and its ligand PD-L1. Known ICBs are: Ipilimumab, a mAb-blocking CTLA4, approved in patients with unresectable or metastatic melanoma. Pembrolizumab, a mAb-blocking PD-1, initially licensed for use in patients with unresectable or metastatic melanoma experiencing disease progression on ipilimumab. Pembrolizumab has been recently made available for other types of cancer (metastatic Non-Small Cell Lung Cancer, Head and Neck Cancer, Hodgkin’s Lymphoma, Urothelial Carcinoma and Gastric Cancer). Nivolumab is another mAb directed to PD-1 approved...
for use in individuals with unresectable or metastatic melanoma non-responding to other treatments, as well as in patients with metastatic NSCLC, or after platinum-based chemotherapy. Atezolizumab is a PD-L1-blocking antibody for the treatment of locally advanced or metastatic urothelial carcinoma. Despite the strong clinical success of cancer immunotherapy with checkpoint inhibitors and other immune modulating agents, most patients still do not experience a durable response (215) and many do not respond at all. To overcome this issue, several strategies combining immune to targeted therapy have been developed.

The gut microbiome, which has a significant influence on the local and systemic immune system, can influence the outcome of ICB therapy in preclinical mouse models and humans (216–219). A recent study on the gut and oral microbiome of a cohort of melanoma patients undergoing an anti-PD-1 therapy revealed crucial differences in the diversity and composition of the patients’ gut microbiome of responders vs. non-responders (216). Analysis of patient fecal microbiome in responding melanoma patients indicated significantly higher relative abundance of bacteria of the Ruminococcaceae family that also correlated with presence of CD8+ T cells in the TME. Fecal microbiota transplantation in germ-free recipients showed that mice which had been transplanted with stool from responders to anti-PD-1 therapy had significantly reduced tumor size and higher density of CD8+ T cells in comparison to mice receiving stool from non-responders to PD-1 blockade (216). Another recent study on different epithelial tumors in mice and patients indicated correlations between clinical responses to ICBs and the relative abundance of Akkermansia muciniphila (217). Hence, the gut microbiome can strongly influence the outcome of cancer patients receiving PD-1 blockade therapy. However, the mechanisms related to these immunomodulatory effects of A. muciniphila remain elusive. It is conceivable that an integral intestinal barrier is associated with a minor systemic inflammation, and specific bacterial families such as Ruminococcaceae and/or A. muciniphila may induce beneficial bacterial metabolites that prevent leaky colon and systemic immunosuppression, paving the way to the possibility to manipulate the gut ecosystem to implement ICB therapy (218).

All recent preclinical and clinical data suggest that the localization, quality, and quantity of non-cancerous cells, including lymphoid and myeloid cells, within the TME play a major role in shaping response to immune checkpoint blockade (Figures 3 and 4). Other TME cells, such as fibroblast and ECs, could

**FIGURE 4** Effects of vascular endothelial growth factor (VEGF) inhibition combined with immunotherapy in the tumor microenvironment. Immune checkpoint blockers (ICBs) combined with antiangiogenic drugs act synergistically on different cell of innate immunity by (i) reducing VEGF in the tumors that supports angiogenesis; (ii) supporting vascular normalization to stabilize blood vessels and enhance therapeutic agent delivery, T cell infiltration, and activation; (iii) blocking dendritic cells, myeloid-derived suppressor cells, T regulatory (Treg)-mediated immunosuppression.
contribute to shaping the immune contest. An emerging role is demonstrated for the angiogenic factor VEGF.

Vascular endothelial growth factor blocks T cell infiltration into the tumor by inhibition of adhesion molecules on ECs (220). VEGF has also been reported to inhibit antigen presentation by DCs, to enhance the Treg expansion, and to mediate PD-1 upregulation on tumor-infiltrated T cells (221, 222). Antiangiogenic treatments such as anti-VEGF antibody bevacizumab and the diverse multi-tyrosine kinase receptor inhibitors targeting the VEGFR family have been largely employed in the clinic, combined with chemotherapy, in particular in colorectal and renal cancer. They have shown significant but moderate benefits in patients’ overall survival (223). Excessive pruning of vessels following anti-VEGF treatment has been reported to associate with increased hypoxia that, through upregulation of CXCL12/CXCR4 axis and HIF1α, supports M2-like TAM, MDSC, and Treg recruitment, thus supporting tumor progression (223). Tumors show considerable variation in their responses to antiangiogenic therapy, however, given the immunosuppressive action of VEGF (47, 222, 224), VEGF inhibitors could combine with the ICBS to enhance therapeutic effects.

Therefore, combination with antiangiogenic agents, and/or anti-inflammatory drugs has a strong rationale (47, 225, 226) but it is still in its infancy. Preclinical and clinical studies in renal cancer showed that the combination of anti-CTLA-4 with sunitinib (227) resulted in decreased Treg and increased CD8+ T cell infiltration (Figure 4). Conversely, increased PD-L1 expression has been observed following treatments with sorafenib, sunitinib, or bevacizumab in a HIF1α-dependent and -independent manner (228). Growing evidence supports the notion that the targeting of VEGF signaling could result in the induction of tumor vasculature normalization, enhancement of immune cells extravasation, and synergy with immunotherapy (229–231). The combination of bevacizumab and ipilimumab has been reported to be associated with clinical benefits in patients with melanoma (232), and has been found to target Galectin-1 (233–235). Blocking of VEGFA and angiopoietin-2 using a bispecific antibody in murine models resulted in activation of cytotoxic T lymphocytes, which upregulated PD-L1, and inhibition of PD-1 axis further improved the efficacy of this therapy (236). Another rationale for the combination of ICBS and antiangiogenic agents is that antiangiogenic agents “normalize” the tumor vasculature, inducing intra-tumor high endothelial venules, thus favoring high T-cell infiltration, antitumor CTL activity, and tumor cell destruction (236, 237). ICBS in combination with antiangiogenic agents may act as a promising strategy also to dampen the proangiogenic features of immune-infiltrating cells, such as TAMs, MDSCs, and NK cells, acting as re-polarizing agents (226, 238, 239).

Chronic inflammation, another relevant hallmark of cancer (3), directly stimulates angiogenesis to support tumor progression (5, 7) and immune suppression (16, 17, 107, 225, 226). The immunosuppressive inflammatory TME is a key obstacle to cancer immunotherapy (Figures 3 and 4). Thus, targeting chronic inflammation could be one strategy to combat the immunosuppressive TME and enhance the activities of ICBS. One example is targeting the PI3Ky, which has a strong effect on myeloid cells, preventing immune suppression and enhancing the effects of ICBS in vivo (240, 241) (Figures 3 and 4). Another example of therapy that could synergize with ICBS is targeting the CXCR2 axis, which recruits neutrophils into the premetastatic niche (98).

The combination of anti-inflammatory agents with ICBS can be exploited to support immunotherapy. Regular use of aspirin, the most commonly employed nonsteroidal anti-inflammatory drug, has been widely reported to reduce incidence and mortality of colorectal cancer (242) and many other adenocarcinomas (243). A recent U.S. population-based study reported a stronger survival association of post-diagnosis aspirin use in CRC patients with lower-level PD-L1 expression when compared with those with higher-level of PD-L1 expression (244). Experimental data supported a synergistic effect between aspirin and anti-PD1 antibody in mutant Braf(V600E) melanoma cells (245). The synergistic effects resulted also in increased T cell-mediated immune responses and decreased PGE2 production (245). In experimental models, we showed that aspirin or the beta-blocker agent atenolol can augment the activity of metformin, a biguanide largely employed in type 2 diabetes management and that have been associated to reduced risk of developing diverse cancers,
including breast cancers (Figure 4), targeting both neoplastic cells and the TME (246, 247). Metformin and phenformin affect the angiogenesis pathway (248–250) and modulate the immune response and the microbiome (251, 252). Phenformin enhances PD-1 immunotherapy (115). CDDO-Im (a synthetic triterpenoid: 1-[2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]jimicadazole) has an extensive documentation as an immunomodulation agent (253–255), and xanthohumol (XN) (a prenylated chalcone flavonoid) is an antileukemia agent (256–259) and is a polarizing agent in murine models of breast cancer (260). Phytochemicals and their synthetic derivatives are able to polarize macrophages inducing anti-tumorigenic phenotype/functions (253, 260–262). For example, we show that NSCLC patient TANKs treated with metformin, CDDO-Im, and XN decreases VEGF production (Figure 5) and increases perforin content. Thus, we would like to indicate the use of non-toxic or low-toxic re-polarization agents endowed with anti-inflammatory chemopreventive properties to be combined with ICBs.

CONCLUSION

The immune checkpoint inhibitors have posed a distinct milestone in cancer therapy. However, several patients do not respond to the ICBS, or have a relapse, with eventual long-term toxicity (i.e., autoimmune diseases). The polarized TME is crucial in the outcome of the patient response to an ICB, thus treating an inflamed or vascularized TME, could theoretically enhance the efficacy of these drugs. We suggest to combine ICBS with drugs that inhibit VEGF (232) or to employ drugs that eliminate the protumor inflammatory cells (for example, trabectedin to eliminate TAMs) or to treat with anti-inflammatory agents that will “re-polarize” the immune cells, for example, the repurposed drugs (metformin) and phytochemicals and their synthetic derivatives (CDDO-Im and XN) or both. Since phytochemicals and their synthetic derivatives often protect the cardiovascular system from chemotherapy induced damage (248, 263, 264), we propose, as a first-line therapy for difficult and metastatic tumors, to pretreat with phytochemicals or synthetic derivatives, then continue treatment and add sequentially a VEGF blocker, ICBS, and chemotherapy (to trigger the immunogenic cell death). This will set the stage for the ICBS to become highly effective in additional patients.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

This work was supported by University of Insubria Fondi di Ateneo per la Ricerca “FAR 2016” and “FAR 2017” and the AIRC (Associazione Italiana per la Ricerca sul Cancro).

REFERENCES

1. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer (2009) 9(4):239–52. doi:10.1038/nrc2618
2. Virchow RLK. Die CELLULARPATHLOGIE in ihrer Begründung auf physiologische und pathologische Gewebelehre. [Cellular Pathology As Based Upon Physiological and Pathological Histology]. Berlin: August Hirschwald (1858). Published in English in 1863 by J. B. Lippincott, Philadelphia.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646–74. doi:10.1016/j.cell.2011.02.013
4. Bruno A, Pagani A, Magnani E, Rossi T, Noonan DM, Cantelmo AR, et al. Inflammatory angiogenesis and the tumor microenvironment as targets for cancer response and prevention. Cancer Treat Rev (2014) 159:401–26. doi:10.1016/0305-738X(64-42-380007-5_23
5. Bruno A, Pagani A, Pulze L, Albini A, Dallaglio K, Noonan DM, et al. Orchestration of angiogenesis by immune cells. Front Oncol (2014) 4:131. doi:10.3389/fonc.2014.00131
6. De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer (2017) 17(8):457–74. doi:10.1038/nrc.2017.51
7. Noonan DM, De Lemme Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory angiogenesis and angiogenesis: decisions and indecisions. Cancer Metastasis Rev (2008) 27(1):31–40. doi:10.1007/s10555-007-9108-5
8. Shaked Y, McAllister S, Fainaru O, Almog N. Tumor dormancy and the angiogenic switch: possible implications of bone marrow-derived cells. Curr Pharm Des (2014) 20(30):4920–33. doi:10.2174/138161281966613112513536
9. Stockmann C, Schaden Dorf D, Klose R, Helfrich I. The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol (2014) 4:69. doi:10.3389/fonc.2014.00069
10. Glass CK, Natoli G. Molecular control of activation and priming in macrophages. Nat Immunol (2016) 17(1):26–33. doi:10.1038/ni.3306
11. Sica A, Erreni M, Allavena P, Porta C. Macrophage polarization in pathology. Cell Mol Life Sci (2015) 72(21):4111–26. doi:10.1007/s00018-015-1995-y
12. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerd t S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41(1):14–20. doi:10.1016/j.immuni.2014.06.008
13. Mantovani A. Reflections on immunological nomenclature: in praise of imperfection. Nat Immunol (2016) 17(3):215–6. doi:10.1038/ni.3354
14. Mantovani A, Marchesi F, Malvesi A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol (2017) 14(7):399–416. doi:10.1038/nrclinonc.2016.217
15. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 117(5):1155–66. doi:10.1172/JCI31422
16. Coussens LM, Zitvogel L, Palucca AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 339(6167):286–91. doi:10.1126/science.1232227
17. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454(7203):436–44. doi:10.1038/nature07205
18. Lan C, Huang X, Lin S, Huang H, Cai Q, Wan T, et al. Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat (2013) 12(3):259–67. doi:10.7785/tcrt.2012.500312
19. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141(1):39–51. doi:10.1016/j.cell.2010.03.014
20. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 15(4):1069–74. doi:10.1677/ERC-08-0036
21. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Expression of M2-polarized macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med (2010) 362(10):875–85. doi:10.1056/NEJMoa0905680
22. Xu J, Escamilla J, Mok S, David J, Priceman S, West B, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the
efficacy of radiotherapy in prostate cancer. Cancer Res (2013) 73(9):2782–94. doi:10.1158/0008-5472.CAN-12-3981

23. Forsell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res (2007) 13(5):1472–9. doi:10.1158/1078-0432.CCR-06-2073

24. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC. Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res (2000) 60(20):5857–61.

25. Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Brading P. Macrophage and mast-cell invasion of cellular tumor islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol (2005) 23(35):8959–67. doi:10.1200/JCO.2005.01.4910

26. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 11(10):889–96. doi:10.1038/ni.1937

27. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the emerged role of macrophages as lymphatic endothelial progenitors. Trends Immunol (2012) 33(3):119–26. doi:10.1016/j.it.2011.12.001

28. Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, et al. Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS One (2011) 6(4):e19495. doi:10.1371/journal.pone.0019495

29. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming by tumor-associated macrophages: from mechanisms to therapy. Immunity (2014) 41(1):49–61. doi:10.1016/j.immuni.2014.06.010

30. Mazzieri R, Pucci F, Motto D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell (2011) 19(4):512–26. doi:10.1016/j.ccc.2011.02.005

31. Tarquinio SB, Alves AM, Nör JE, Nedel F, Gomes FG. Tumor angiogenesis as a novel strategy for cancer therapy. Cancers (Basel) (2012) 4(3):618–57. doi:10.3390/cancers4030618

32. Chung FT, Lee KY, Wang CW, Heh CC, Chen YF, Chen HW, et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer (2012) 131(1):274–81. doi:10.1002/ijc.27403

33. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell (2016) 164(6):1233–47. doi:10.1016/j.cell.2016.01.049

34. Zhou H, Binmadi NO, Yang YH, Proia P, Basile JR. Semaphorin 4D cooperates with liver metastasis in pancreatic cancer: a dose-escalation phase 1 study. Lancet Oncol (2015) 16(8):849–56. doi:10.1016/s1470-2045(15)00132-1

35. Cassier PA, Italiano A, Gomez-Roca CA, Le Tourneau C, Toulmonde M, Halama N, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol (2016) 17(1):34–40. doi:10.1016/S1470-2045(15)00016-3

36. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood (2012) 119(13):3164–75. doi:10.1182/blood-2011-08-376426

37. Gil-Bernabé AM, Ferjancic S, Tlalka M, Zhao L, Allen PD, Im JH, et al. Targeting of tumour-infiltrating lymphocytes/macrophages by siRNA-mediated coagulation. Nat Med (2017) 23(5):600–7. doi:10.1038/nm.4382

38. Scimone M, Grohmann M, Grueter M, Heinrich M, Stahl J, Brück M, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type popular histiocytosis (Histiocytosis X) of the bone: a multicentre, open-label, phase 2 study. Lancet Oncol (2015) 16(10):1209–18. doi:10.1016/s1470-2045(15)00197-0

39. Palucka AK, Coussens LM. The basis of oncoimmunology. Cell (2016) 164(6):1233–47. doi:10.1016/j.cell.2016.01.049

40. Mortara L, Benest AV, Bates DO, Noonan DM. Can the co-dependence of the immune system and angiogenesis facilitate pharmaceutical targeting of tumours? Curr Opin Pharmacol (2017) 35:66–74. doi:10.1016/j.coph.2017.05.009

41. Chung FT, Lee KY, Wang CW, Heh CC, Chen YF, Chen HW, et al. Tumor-associated macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. Med Oncol (2014) 31(8):127. doi:10.1007/s12032-014-0127-0

42. Mortara L, Benest AV, Bates DO, Noonan DM. Can the co-dependence of the immune system and angiogenesis facilitate pharmaceutical targeting of tumours? Curr Opin Pharmacol (2017) 35:66–74. doi:10.1016/j.coph.2017.05.009

43. Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou W, et al. M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. Med Oncol (2014) 31(8):127. doi:10.1007/s12032-014-0127-0

44. Hughes R, Qian BZ, Rowan C, Muthana M, Kekkiläkioglu I, Olson OC, et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res (2015) 75(17):3479–91. doi:10.1158/0008-5472.CAN-14-3587

45. Mazzieri R, Pucci F, Motto D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell (2011) 19(4):512–26. doi:10.1016/j.ccc.2011.02.005
60. Junankar S, Shay G, Jurczyhuk J, Ali N, Down J, Pocock N, et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskelatal target of bisphosphonate action in cancer. *Cancer Discov* (2015) 5(135-42. doi:10.1158/2159-8290.CD-14-0621

61. Van Acker HH, Anguille S, Willemen Y, Smits El, Vantendele VE. Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. *Pharmacol Ther* (2016) 158:24–40. doi:10.1016/j.pharmthera.2015.11.008

62. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. *Science* (2011) 331(6024):1612–6. doi:10.1126/science.1198443

63. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. *Clin Cancer Res* (2013) 19(22):6286–95. doi:10.1158/1078-0432.CCR-13-1320

64. Allavena P, Germano G, Belgiovine C, D’Incalci M, Mantovani A. Role of macrophage targeting in the antitumor activity of trabectedin. *Cancer Cell* (2013) 23(2):249–62. doi:10.1016/j.ccr.2013.01.008

65. Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer. *Int J Cancer* (2016) 139(2):446–56. doi:10.1002/ijc.31076

66. Jensen HK, Donskov F, Marcusson N, Nordmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. *J Clin Oncol* (2009) 27(28):4709–17. doi:10.1200/JCO.2008.18.9498

67. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. *J Hepatol* (2011) 54(3):948–53. doi:10.1016/j.jhep.2011.06.041

68. Rao HL, Chen JW, Li M, Xiao YB, Fu J, Zeng YX, et al. Increased intratumoral neutrophil in colorectal cancers correlates closely with malignant phenotype and predicts patients’ adverse prognosis. *PLoS One* (2012) 7(1):e30806. doi:10.1371/journal.pone.0030806

69. Trellakis S, Bruderek K, Dumitru C, Stankovic M, Bankfalvi A, et al. Polymorphonuclear granulocytes in human head and neck cancer: enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. *Int J Cancer* (2011) 129(9):2183–93. doi:10.1002/ijc.25892

70. Albini et al. Proangiogenic Activity of Innate Immunity in Cancer

71. Scapini P, Morini M, Taniguchi T, Bellerti M, Noonan D, et al. Generation of biologically active angiostatin kringles 1-3 by activated human neutrophils. *J Immunol* (2002) 168(5):5798–804. doi:10.4049/jimmunol.168.11.5798

72. Dozzi M, Nicoletti I, Turco R, Cerri S, Mazzucchelli L, et al. Neutrophil-derived angiogenic factor-α induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. *J Immunol* (2004) 172(8):5033–40. doi:10.4049/jimmunol.172.8.5034

73. Scapini P, Nesi L, Morini M, Tanghetti E, Bellerti M, Noonan D, et al. Generation of biologically active angiostatin kringles 1-3 by activated human neutrophils. *J Immunol* (2002) 168(5):5798–804. doi:10.4049/jimmunol.168.11.5798

74. Cisternino MA, Golebiowski E, Kucinskas L, Bankfalvi A, et al. Neutrophil recruitment and function in health and inflammation. *Nat Rev Immunol* (2013) 13(3):159–75. doi:10.1038/nri3399
98. Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell (2016) 31(6):1089–100. doi:10.1016/j.ccell.2016.04.014

99. Tabarikis S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, et al. Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases. Breast Cancer Res (2015) 17:45. doi:10.1186/s13058-015-0558-3

100. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep (2015) 11(4):377–91. doi:10.1016/j.celrep.2015.03.055

101. Ma Y, Shurin GV, Gutkin DW, Shurin MR. Tumor associated regulatory dendritic cells. Semin Cancer Biol (2012) 22(4):298–306. doi:10.1016/j.semcancer.2012.02.010

102. Shurin GV, Ma Y, Shurin MR. Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron (2013) 6(2):159–67. doi:10.1007/s13207-013-0133-3

103. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 125(9):3356–64. doi:10.1172/JCI80005

104. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. J Leukoc Biol (2016) 100(3):435–42. doi:10.1189/jlb.0315-034.R

105. Liang S, De Santis M, Suardi N, Bronte V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 129(5):3365–76. doi:10.1172/JCI80006

106. Kumar V, Patel S, Tycagow E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol (2016) 37(3):208–20. doi:10.1016/j.ti.2016.01.004

107. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression. Nat Rev Immunol (2015) 15(3):174–80. doi:10.1038/nri3175

108. Benci-Falco D, Zampieri F, Bosco S, De Santis M, Briganti E, Bronte V. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res (2015) 3(11):1236–47. doi:10.1158/2326-066X.CIR-15-0036

109. Park J, Lee SE, Hur J, Hong EB, Choi JI, Yang JM, et al. M-CSF from cancer cells induces fatty acid synthase and PPARbeta/delta activation in tumor myeloid cells, leading to tumor progression. Cell Rep (2015) 10(9):1614–25. doi:10.1016/j.celrep.2015.02.024

110. Kim SH, Li M, Troulis S, Zhang Y, Pasca di Magliano M, Swanson KD, et al. Phenformin inhibits myeloid-suppressor cell differentiation and functions in pathology. J Leukoc Biol (2017) 102(2):325–34. doi:10.1189/jlb.0416-476R

111. Hossain F, Al-Khami AA, Wyczewchowska D, Hernandez C, Zheng L, Reiss K, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res (2015) 3(11):1236–47. doi:10.1158/2326-066X.CIR-15-0036

112. Chae CS, Teran-Cabanillas E, Cubillos-Ruiz JR. Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. Cancer Immunol Immunother (2017) 66(6):969–77. doi:10.1007/s00262-017-1958-2

113. Scarlatt UK, Rukwoski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 209(3):493–506. doi:10.1084/jem.20111413

114. Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol (2016) 37(12):855–65. doi:10.1016/j.ti.2016.09.006

115. Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol (2017) 45:43–51. doi:10.1016/j.coi.2017.01.002

116. Scarlett UK, Rukwoski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med (2012) 209(3):493–506. doi:10.1084/jem.20111413

117. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 202(7):919–29. doi:10.1084/jem.20050463

118. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, et al. Tumor evasion of the immune system by converting CD4+CD25− T cells into CD4+CD25+ regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 178(5):2883–92. doi:10.4049/jimmunol.178.5.2883

119. Yang M, Ma C, Liu S, Shao Q, Gao W, Song B, et al. HIF-dependent induction of adenosine receptor A2b drives human dendritic cells to a Th2-stimulating phenotype under hypoxia. Immunity Cell Biol (2010) 88(2):165–71. doi:10.1017/ icb.2009.77

120. Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res (2017) 5(1):1–8. doi:10.1158/2326-066X.CIR-16-0297

121. Varricchi G, Galdiero MR, Moffredo S, Marone G, Iannone R, Marone G, et al. Are mast cells MASTERs in cancer? Front Immunol (2017) 8:424. doi:10.3389/fimmu.2017.00424

122. Chen CY, St John AL, Abraham SN. Plasticity in mast cell responses during bacterial infections. Curr Opin Microbiol (2012) 15(1):78–84. doi:10.1016/j.romi.2011.10.007

123. Marichal T, Starkl P, Reber LL, Klesniokoff J, Oettgen HC, Tsai M, et al. A beneficial role for immunoglobulin E in host defense against honeybee venom. Immunity (2013) 39(5):963–75. doi:10.1016/j.immuni.2013.10.005

124. Palm NW, Rosenstein RK, Yu S, Schenten DD, Florsheim E, Medzhitov R. Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. Immunity (2013) 39(5):976–85. doi:10.1016/j.immuni.2013.10.006

125. Wang Z, Lai Y, Bernstein JJ, Macleod DT, Cogen AL, Moss B, et al. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. J Immunol (2012) 188(1):345–57. doi:10.4049/jimmunol.1101703

126. Marone G, Varricchi G, Moffredo S, Granata F, Maiso B, et al. Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides. J Immunol (2012) 188(1):345–57. doi:10.4049/jimmunol.1101703

127. Jecheci E, Rigoni A, Bongiovanni L, Arloti I, Botti L, Parenza M, et al. Immunotip spares c-kit-expressing prostate neuroendocrine tumors, whereas kills seminal vesicle epithelial-stromal tumors by targeting PDGFR-beta. Mol Cancer Ther (2017) 16(2):365–75. doi:10.1158/1535-7186.MCT-16-0466

128. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendt O, Werb Z, et al. Inflammatory mast cells up-regulate angiogenesis during...
squamous epithelial carcinogenesis. Genes Dev (1999) 13(11):1382–97. doi:10.1101/gad.13.11.1382

139. de Souza Junior DA, Santana AC, da Silva EZ, Oliver C, Jamur MC. The role of mast cell specific chymases and tryptases in tumor angiogenesis. Biomed Res Int (2015) 2015:142359. doi:10.1155/2015/142359

140. Chen Y, Li C, Xie H, Fan Y, Yang Z, Ma J, et al. Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K – ∼ AKT – > GS3Kbeta – > AM signaling. Oncogene (2017) 36(20):2879–88. doi:10.1038/onc.2016.442

141. Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamiglio G, Rocco S, et al. Targeting mast cells tryptases in tumor microenvironment: a potential antiangiogenic strategy. Biomed Res Int (2014) 2014:154702. doi:10.1155/2014/154702

142. Ammendola M, Patruno R, Sacco R, Marech I, Sammarco G, Zuccali V, et al. Mast cells positive to tryptase and tumour-associated macrophages correlate with angiogenesis in locally advanced colorectal cancer patients undergone to surgery. Expert Opin Ther Targets (2016) 20(5):533–40. doi:10.1517/14728222.2016.1158811

143. Vyzoukaki R, Tsirakis G, Gappa CA, Androulakis N, Kokonozaki M, Tzardi M, et al. Correlation of mast cell density with angiogenic cytokines in patients with active myeloma. Clin Ther (2016) 38(2):297–301. doi:10.1016/j.clinthera.2015.11.022

144. Nico B, Mangieri D, Crivellato E, Vacca A, Ribatti D. Mast cells contribute to vasculogenic mimicry in multiple myeloma. Stem Cells Dev (2008) 17(1):19–22. doi:10.1089/scd.2007.0312

145. Ammendola M, Sacco R, Sammarco G, Donato G, Montemurro S, Ruggieri E, et al. Correlation between serum tryptase, mast cells positive to tryptase and microvascular color in colorectal cancer patients: possible biological-clinical significance. PLoS One (2014) 9(6):e99952. doi:10.1371/journal.pone.0099512

146. Ranieri G, Ammendola M, Patruno R, Celano G, Zito FA, Montemurro S, et al. Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol (2009) 35(1):115–20. doi:10.3892/ijo_0000319

147. Patil RS, Bhat SA, Dar AA, Chiplunkar SV. Jekyll and Hyde story of IL17- dependent angiogenesis. J Immunol (2013) 191(11):5711–5. doi:10.4049/jimmunol.1300776

148. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, et al. gammadeltaT17 cells promote renal cell carcinoma angiogenesis by modulating PI3K – ∼ AKT – > GS3Kbeta – > AM signaling. Oncogene (2017) 36(20):2879–88. doi:10.1038/onc.2016.442

149. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with progression of tumor by promoting angiogenesis. Eur J Immunol (2010) 40(7):2197–207. doi:10.1002/eji.200940157

150. Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in tumor immunity. Biochem Biophys Res Commun (2011) 407(2):348–54. doi:10.1016/j.bbrc.2011.03.021

151. Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin S, et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GH signaling pathway in non-small cell lung cancer. Sci Rep (2015) 5:16053. doi:10.1038/srep16053

152. Patil RS, Shah SU, Shikhande SV, Goel M, Dikshit RP, Chiplunkar SV, et al. IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer (2016) 139(4):869–81. doi:10.1002/ijc.30134

153. Campbell JJ, Ebsworth K, Ertl LS, McMahon JP, Newland D, Wang Y, et al. IL-17-secreting gammadelta T cells are completely dependent upon CCR6 for homing to inflamed skin. J Immunol (2017) 199(9):3129–36. doi:10.4049/jimmunol.1700826

154. Carregà P, Campana S, Bonaccorsi I, Ferlazzo G, The Yin and Yang of innate lymphoid cells in cancer. Immunol Lett (2016) 179:29–35. doi:10.1016/j.imlet.2016.06.003

155. Mattner J, Wirtz S. Friend or foe? The ambiguous role of innate lymphoid cells in cancer development. Trends Immunol (2017) 38(1):29–38. doi:10.1016/j.it.2016.10.004

156. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. In innate lymphoid cells – a proposal for uniform nomenclature. Nat Rev Immunol (2013) 13(2):145–9. doi:10.1038/nri3365

157. Buonocore S, Ahern PP, Ulhig HH, Ivanov II, Littman DR, Maloy KJ, et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature (2014) 507(7491):1371–5. doi:10.1038/nature13049

158. Chang YJ, Kim HY, Albacker LA, Baumgartl N, McKenzie AN, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol (2011) 12(7):631–8. doi:10.1038/ni.2045

159. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2-type cytokines in protease allergen-induced airway inflammation. Immunology (2012) 136(3):451–63. doi:10.1111/j.1365-2567.2011.12020

160. Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonnenberg GF, et al. Lung natural helper cells are a critical source of Th2-type cytokines in protease allergen-induced airway inflammation. Immunology (2012) 136(3):451–63. doi:10.1111/j.1365-2567.2011.12020

161. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2-type cytokines in protease allergen-induced airway inflammation. Immunology (2012) 136(3):451–63. doi:10.1111/j.1365-2567.2011.12020

162. Roediger B, Kyle R, Yip KH, Sumaria N, Guy TV, Kim BS, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Commun (2013) 4:1469. doi:10.1038/ncomms1469

163. Acs G, Jordan T, Marsters SA, Coutinho A, Allman J, Woolf AD, et al. Cancer immunosurveillance by tissue resident innate lymphoid cells and innate-like T cells. Cell (2016) 164(3):365–77. doi:10.1016/j.cell.2016.01.002

164. van Beek JJP, Martens AWJ, Bakdash G, de Vries IJM. In innate lymphoid cells in tumor immunity. Biomedicines (2016) 4(1):E7. doi:10.3390/biomedicines4010007

165. Jovanovic IP, Jovanovic IP, Jovanovic IP, Jovanovic IP, Jovanovic IP, Jovanovic IP. In innate lymphoid cells in tumor immunity. Biomedicines (2016) 4(1):E7. doi:10.3390/biomedicines4010007

166. Zhong S, Sun LC, Wu J, Wu J, Wu J, Wu J, Wu J. In innate lymphoid cells in tumor immunity. Biomedicines (2016) 4(1):E7. doi:10.3390/biomedicines4010007

167. Zhong S, Sun LC, Wu J, Wu J, Wu J, Wu J. In innate lymphoid cells in tumor immunity. Biomedicines (2016) 4(1):E7. doi:10.3390/biomedicines4010007

168. Zhong S, Sun LC, Wu J, Wu J, Wu J, Wu J. In innate lymphoid cells in tumor immunity. Biomedicines (2016) 4(1):E7. doi:10.3390/biomedicines4010007

169. Zhong S, Sun LC, Wu J, Wu J, Wu J, Wu J. In innate lymphoid cells in tumor immunity. Biomedicines (2016) 4(1):E7. doi:10.3390/biomedicines4010007
177. He D, Li H, Yusuf N, Elmets CA, Li J, Mounitz JD, et al. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. *J Immunol* (2010) 184(3):1281–8. doi:10.4049/jimmunol.0902794

178. Li Q, Liu L, Zhang Q, Liu S, Ge D, You Z. Interleukin-17 indirectly promotes *IL-17* promotes tumor growth. *Cancer Res Treat* (2014) 46(3):297–306. doi:10.4143/crt.2014.46.3.297

179. Kirchberger S, Royston DJ, Boulard O, Thornton E, Franchini F, Szabady RL, et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. *J Exp Med* (2015) 210(5):917–31. doi:10.1084/jem.20122308

180. Irshad S, Flores-Bortja F, Lawler K, Monypenny J, Evans R, Male V, et al. IL-17 promotes tumor growth and manipulation for therapeutic intervention. *Front Immunol* (2016) 7:407. doi:10.3389/fimmu.2016.00407

181. Tian Z, van Velkinburgh JC, Wu Y, Li B. Innate lymphoid cells involve in tumorigenesis. *Int J Cancer* (2016) 138(1):2–9. doi:10.1002/ijc.29443

182. Figenschau SL, Fismen S, Fenton KA, Fenton C, Mortensen ES. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. *Front Immunol* (2016) 7:171. doi:10.3389/fimmu.2015.00278

183. Sautès-Fridman C, Lawand M, Giraldo NA, Kaplon H, Germain C, Fridman WH, et al. IL-17A contributes to the formation of tertiary lymphoid structures in patients with non-small cell lung cancer. *Neoplasia* (2013) 15(2):133–42. doi:10.1593/121758

184. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cells. *Cytometry B Clin Cytom* (2007) 70(1):1–11. doi:10.1002/cyto.b.20230

185. Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R, et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. *Front Immunol* (2016) 7:407. doi:10.3389/fimmu.2016.00407

186. Shikhagaie MM, Björklund ÅK, Mjösberg J, Erjefält JS, Cornelissen AS, et al. IL-17 promotes tumor growth and manipulation for therapeutic intervention. *Front Immunol* (2016) 7:171. doi:10.3389/fimmu.2015.00278

187. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells on the biology of human natural killer cells. *Front Immunol* (2016) 7:171. doi:10.3389/fimmu.2015.00278

188. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subsets. *Trends Immunol* (2016) 37(9):438–48. doi:10.1016/j.ti.2016.06.003

189. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human natural killer cell subsets. *Front Immunol* (2016) 7:171. doi:10.3389/fimmu.2015.00278

190. DeMaria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subsets. *Trends Immunol* (2016) 37(9):438–48. doi:10.1016/j.ti.2016.06.003

191. Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Hong KD, et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. *Proc Natl Acad Sci U S A* (2007) 104(9):3378–83. doi:10.1073/pnas.0611089104

192. Cerdeira AS, Rajakumar A, Royle CM, Lo A, Husain Z, Thadhanai RL, et al. Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. *J Immunol* (2013) 190(8):3939–48. doi:10.4049/jimmunol.1202582

193. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. *Trends Immunol* (2001) 22(11):633–40. doi:10.1016/s1476-6854(01)00206-9

194. Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, et al. IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity. *Nature* (2017) 551(7678):110–4. doi:10.1038/nature24293
Gopalakrishnan V, Spencer CN, Nezi I, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (2018) 359(6371):97–103. doi:10.1126/science.aan3706

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science (2018) 359(6371):91–7. doi:10.1126/science.aan3706

Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol (2017) 15(8):465–78. doi:10.1038/nrmicro.2017.44

Garrett WS. Cancer and the microbiota. Science (2015) 348(6230):80–6. doi:10.1126/science.aaa4972

Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J (2006) 20(6):621–30. doi:10.1096/fj.05-4493com

Ohm JE, Carbone DP. VEGF as a mediator of tumor-associated immuno-deficiency. Immunol Res (2001) 23(2–3):263–72. doi:10.1385/IR:23:2-3:263

Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet AL, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (2018) 359(6371):91–7. doi:10.1126/scitranslmed.aak6979

Routy B, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2014) 74(10):2943–8. doi:10.1158/0008-5472.CAN-13-4354

Dallaglio K, Bruno A, Cantelmo AR, Esposito AI, Ruggiero L, Orecchioni S, et al. Anti-angiogenic treatment reprograms the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 109(43):17561–6. doi:10.1073/pnas.1215397109

Shirimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 70(15):6171–80. doi:10.1158/0008-5472.CAN-10-1513

Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 73(10):2943–8. doi:10.1158/0008-5472.CAN-13-4354

Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. Combined anti-VEGF and anti-CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes. Cancer Immunol Res (2017) 5(6):446–54. doi:10.1158/2326-0666.CIR-16-0385

Schmittnaegel M, Rigamonti N, Kadioglu E, Cassarà A, Wyser Rmili C, Kialalainen A, et al. Dual angiopoietin-2 and VEGFα inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med (2017) 9(385):eaak9670. doi:10.1126/scitranslmed.aak9670

Allen E, Jabouille A, Rivera LB, Lodewijcks I, Missiaen R, Steri V, et al. Combined antiangiogenic and anti-PD-1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med (2017) 9(385):eaak9679. doi:10.1126/scitranslmed.aak9679

Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 17(9):1025–36. doi:10.1038/ni.3518

Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy (2017) 9(3):289–302. doi:10.2217/imt-2016-0135

De Henaux O, Rausch M, Winkler D, Campesato LE, Liu C, Cymerman DH, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kαamma in myeloid cells. Nature (2016) 539(7629):443–7. doi:10.1038/ nature20554

Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3Kαamma is a molecular switch that controls immune suppression. Nature (2016) 539(7629):437–42. doi:10.1038/nature19834

Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer (2016) 16(3):173–86. doi:10.1038/nrclinonc.2015.34

Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol (2015) 26(1):47–57. doi:10.1093/annonc/mdu225

Hamada T, Cao Y, Qian ZR, Masugi Y, Nowalk JA, Yang J, et al. Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status. J Clin Oncol (2017) 35(16):1836–44. doi:10.1200/JCO.2016.70.7547

Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immu-nity. Cell (2015) 162(6):1257–70. doi:10.1016/j.cell.2015.08.015

Albini A, DeCensi A, Cavalli F, Costa A. Cancer prevention and interception: a new era for chemopreventive approaches. Clin Cancer Res (2016) 22(17):4322–7. doi:10.1158/1078-0432.CCR-16-0695

Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironmental cells. Sci Rep (2016) 6:18673. doi:10.1038/srep18673

Albini A, Bassani B, Baci D, Dallaglio K, Gallazzi M, Corradino P, et al. Nutraceuticals and "repurposed" drugs of phytochemical origin in prevention and interception of chronic degenerative disease and cancer. Curr Med Chem (2018). doi:10.2174/09298673246667092014130

Dallaglio K, Bruno A, Cantelmo AR, Esposito AJ, Ruggiero L, Orecchioni S, et al. Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis (2014) 35(5):1055–66. doi:10.1093/carcin/bgu001

Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, et al. The bignuandines metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironmental cells. Int J Cancer (2015) 136(6):ES34–44. doi:10.1002/ijc.29193

Pollak M. The effects of metformin on gut microbiota and the immune system as research frontiers. Diabetologia (2017) 60(9):1662–7. doi:10.1007/s00125-017-4352-x

Ekawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A (2015) 112(6):1809–14. doi:10.1073/pnas.1417631112

Ball MS, Shipman EP, Kim H, Liby KT, Pioli PA. CDDO-Me redirects activation of breast tumor associated macrophages. PLoS One (2016) 11(2):e0149600. doi:10.1371/journal.pone.0149600

Fitzpatrick LR, Stonesifer E, Small JS, Liby KT. The synthetic triterpenoid (CDDO-Im) inhibits STAT1, as well as IL-17, and improves DSS-induced colitis in mice. Inflammopharmacology (2014) 22(6):341–9. doi:10.1007/s10787-014-0203-2

Leal AS, Sporn MB, Pioli PA, Liby KT. The triterpenoid CDDO-imidazole reduces immune cell infiltration and cytokine secretion in the

Frontiers in Immunology | www.frontiersin.org 18 April 2018 | Volume 9 | Article 527
KrasG12D;Pdx1-Cre (KC) mouse model of pancreatic cancer. *Carcinogenesis* (2016) 37(12):1170–9. doi:10.1093/carcin/bgw099

256. Benelli R, Venè R, Ciarlo M, Carlone S, Barbieri O, Ferrari N, et al. The AKT/NF-kappaB inhibitor xanthohumol is a potent anti-lymphocytic leukemia drug overcoming chemoresistance and cell infiltration. *Biochem Pharmacol* (2012) 83(12):1634–42. doi:10.1016/j.bcp.2012.03.006

257. Dell’Eva R, Ambrosini C, Vannini N, Piaggio G, Albini A, Ferrari N. AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. *Cancer* (2007) 110(9):2007–11. doi:10.1002/cncr.23017

258. Lust S, Vanhoecke B, Janssens A, Philippe J, Bracke M, Offner F. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. *Mol Nutr Food Res* (2005) 49(9):844–50. doi:10.1002/mnfr.200500045

259. Monteghirfo S, Tosetti F, Ambrosini C, Stigliani S, Pozzi S, Frassoni F, et al. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. *Mol Cancer Ther* (2008) 7(9):2692–702. doi:10.1158/1535-7163.MCT-08-0132

260. Zhang W, Pan Y, Gou P, Zhou C, Ma L, Liu Q, et al. Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model. *Oncol Rep* (2018) 39(1):280–8. doi:10.3892/or.2017.6094

261. Jang JY, Lee JK, Jeon YK, Kim CW. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. *BMC Cancer* (2013) 13:421. doi:10.1186/1471-2407-13-421

262. Mukherjee S, Baidoo JNE, Sampat S, Mancuso A, David L, Cohen LS, et al. Liposomal TriCurin, a synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor-associated microglia/macrophages, and eliminates glioblastoma (GBM) and GBM stem cells. *Molecules* (2018) 23(1):E201. doi:10.3390/molecules23010201

263. Ferrari N, Tosetti F, De Flora S, Donatelli F, Sogno I, Noonan DM, et al. Diet-derived phytochemicals: from cancer chemoprevention to cardio- oncolgical prevention. *Carr Drug Targets* (2011) 12(13):1909–24. doi:10.2174/138945011798184227

264. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. *J Natl Cancer Inst* (2010) 102(1):14–25. doi:10.1093/jnci/djp440

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Albini, Bruno, Noonan and Mortara. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.